RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-
small-cell lung cancers (NSCLCs),–. Inhibition of the RAS oncoproteins has proven difficult …

The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …

Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via
Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the …

The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an
important role in signal transduction downstream of growth factor receptor signalling and …

The role of KRAS, when activated through canonical mutations, has been well established in
cancer. Here we explore a secondary means of KRAS activation in cancer: focal high-level …

New cancer therapies are likely to arise from an in-depth understanding of the signaling
networks influencing tumor initiation, progression and metastasis. We show a fundamental …

KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a
longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react …

Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …

Cancer cells bearing distinct KRAS mutations exhibit variable sensitivity to SHP2 inhibitors
(SHP2i). Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i …

FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …